CMS expands coverage for three drug regimen to fight nausea during chemotherapy

September 3rd, 2014 - Scott Kraft
Categories:   Coding   National Coverage Determinations (NCD)  

Physician practices will soon be able to get paid for use of a three-drug antiemetic regimen used to prevent nausea and vomiting by patients receiving chemotherapy for an expanded list of chemotherapy drugs, under a National Coverage Determination recently posted by CMS. The change in coverage is effective retroactive to May 29, 2013, though MACs will have until July 7, 2014, to implement the change.

The three drug regimen – an oral aprepitant (J8501), an oral 5Ht3 antagonist (Q0166, Q0179, Q0180) and oral dexamethasone (J8540) – is already covered for nine chemotherapy agents. The NCD expands coverage to cases when the patient is receiving one of these 11 chemotherapy agents being added to the covered list:
  • Alemtuzumab (J9010)
  • Azacitidine (J9025)
  • Bendamustine (J9033)
  • Carboplatin (J9045)
  • Clofarabine (J9027)
  • Cytarabine (J9098, J9100, J9110)
  • Daunorubicin (J9150, J9151)
  • Idarubicin (J9211)
  • Ifosfamide (J9208)
  • Irinotecan (J9206)
  • Oxaliplatin (J9263)

Individual MACs will have the discretion to determine coverage for any other oral three-drug regimens that may reduce nausea or vomiting with either the listed chemotherapy agents or others. Any new FDA-approved drug that meets the criteria for use with this three-drug regimen should be billed with unspecified code Q0181 until a specific code is assigned to the drug.

Any claims with dates of service of on or after May 29, 2013 that were denied may be resubmitted for payment. Use of oral aprepitant code J8501 or the not otherwise classified code Q0181 will be denied for services on or after May 29, 2013, if the diagnosis codes V58.11 or Z51.11 are not on the claim.

The three-drug regimen must be administered either immediately before or within 48 hours after anti-cancer chemotherapy and would replace a covered non self-administered drug.


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

COVID Vaccine Coding Changes as of November 1, 2023
October 26th, 2023 - Wyn Staheli
COVID vaccine changes due to the end of the PHE as of November 1, 2023 are addressed in this article.
Medicare Guidance Changes for E/M Services
October 11th, 2023 - Wyn Staheli
2023 brought quite a few changes to Evaluation and management (E/M) services. The significant revisions as noted in the CPT codebook were welcome changes to bring other E/M services more in line with the changes that took place with Office or Other Outpatient Services a few years ago. As part of CMS’ Medicare Learning Network, the “Evaluation and Management Services Guide” publication was finally updated as of August 2023 to include the changes that took place in 2023. If you take a look at the new publication (see references below),....
Can We Score Interpretation of an EKG Towards E/M Medical Decision Making?
October 10th, 2023 - Aimee Wilcox
When EKGs are performed in the facility setting or even in the physician's office, what are the requirements for reporting the service and who gets credit for scoring data points for Evaluation and Management (E/M) medical decision making (MDM)? Let's take a look at a few coding scenarios related to EKG services to get a better understanding of why this can be problematic.
Accurately Reporting Signs and Symptoms with ICD-10-CM Codes
October 5th, 2023 - Aimee Wilcox
Coders often find themselves unsure of when to report a sign or symptom code documented in the medical record. Some coders find their organization has an EHR that requires a working diagnosis, which is usually a sign or symptom, be entered to order a test or diagnostic study or image. Understanding the guidelines surrounding when signs and symptoms should be reported is the first step in correct coding so let's take a look at some scenarios.
The 2024 ICD-10-CM Updates Include New Codes for Reporting Metabolic Disorders and Insulin Resistance
September 19th, 2023 - Aimee Wilcox
Diabetes is a chronic disease that just seems to consistently be increasing instead of improving resulting in a constant endeavor by medical researchers to identify causal effects and possible treatments. One underlying or precipitating condition that scientists have identified as a precipitating factor in the development of diabetes is insulin resistance, which is a known metabolic disorder. As data becomes available through claims reporting, additional code options become possible with ICD-10-CM.
Documenting and Reporting Postoperative Visits
September 12th, 2023 - Aimee Wilcox
Sometimes we receive questions regarding documentation requirements for specific codes or coding requirements and we respond with information and resources to support our answers. The following question was recently submitted: Are providers required to report postoperative services on claims using 99024, especially if there is no payment for that service? What documentation is required if you are reporting an unrelated Evaluation and Management (E/M) service by the same physician during the postoperative period? 
Understanding Gastroesophageal Reflux Disease and ICD-10-CM Coding
August 22nd, 2023 - Aimee Wilcox
Gastroesophageal reflux disease or GERD for short, is a disease that impacts millions of Americans on a weekly basis. Symptoms are uncomfortable, as are some of the tests used to diagnose it, but understanding the disease, tests, and treatments helps us better understand how to code the disease using ICD-10-CM codes.

Home About Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2023 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association